Tadas Naujokaitis1, Vilma Jurate Balciuniene2. 1. Faculty of Medicine, Lithuanian University of Health Sciences, Kaunas, Lithuania. 2. Department of Ophthalmology, Hospital of the Lithuanian University of Health Sciences Kauno Klinikos, Kaunas, Lithuania.
Abstract
PURPOSE: To assess injection patterns and vision outcomes in patients receiving intravitreal ranibizumab injections for diabetic macular edema in a real-world clinical setting. METHODS: Retrospective chart review involving 74 eyes of 62 patients who started ranibizumab treatment for diabetic macular edema at the Hospital of the Lithuanian University of Health Sciences Kauno Klinikos. Data collected included follow-up visits, injections administered, and best-corrected visual acuity (BCVA). RESULTS: Median follow-up duration was 652.5 days (min 365; max 914). Over the first year, eyes received a median of 4 injections (min 1; max 10). Among eyes with 2-year follow-up and injections during the second year, there was a median of 3 injections (min 1; max 6) over the second year. The BCVA improved by a median of 5 letters 365 ± 60 days and 730 ± 60 days after baseline. At the first visit ≥365 days after baseline, 13.5% of eyes gained ≥15 letters from baseline while 6.8% of eyes lost ≥15 letters. For 74.3% of eyes, BCVA improved (gain of ≥5 letters) or remained stable (gain/loss of ≤4 letters). CONCLUSION: Intravitreal ranibizumab for diabetic macular edema was effective in a real-world clinical setting, with most eyes gaining or maintaining vision. Compared with randomized prospective clinical trials, patients received less frequent injections and achieved lower vision gains.
PURPOSE: To assess injection patterns and vision outcomes in patients receiving intravitreal ranibizumab injections for diabetic macular edema in a real-world clinical setting. METHODS: Retrospective chart review involving 74 eyes of 62 patients who started ranibizumab treatment for diabetic macular edema at the Hospital of the Lithuanian University of Health Sciences Kauno Klinikos. Data collected included follow-up visits, injections administered, and best-corrected visual acuity (BCVA). RESULTS: Median follow-up duration was 652.5 days (min 365; max 914). Over the first year, eyes received a median of 4 injections (min 1; max 10). Among eyes with 2-year follow-up and injections during the second year, there was a median of 3 injections (min 1; max 6) over the second year. The BCVA improved by a median of 5 letters 365 ± 60 days and 730 ± 60 days after baseline. At the first visit ≥365 days after baseline, 13.5% of eyes gained ≥15 letters from baseline while 6.8% of eyes lost ≥15 letters. For 74.3% of eyes, BCVA improved (gain of ≥5 letters) or remained stable (gain/loss of ≤4 letters). CONCLUSION: Intravitreal ranibizumab for diabetic macular edema was effective in a real-world clinical setting, with most eyes gaining or maintaining vision. Compared with randomized prospective clinical trials, patients received less frequent injections and achieved lower vision gains.
Authors: Nancy M Holekamp; Joanna Campbell; Arghavan Almony; Herbert Ingraham; Steven Marks; Hitesh Chandwani; Ashley L Cole; Szilárd Kiss Journal: Am J Ophthalmol Date: 2018-04-21 Impact factor: 5.258
Authors: Connie M Wu; Annie M Wu; Paul B Greenberg; Fei Yu; Flora Lum; Anne L Coleman Journal: Ophthalmic Surg Lasers Imaging Retina Date: 2018-04-01 Impact factor: 1.300
Authors: Donald S Fong; Tiffany Q Luong; Richard Contreras; Jennifer J Jimenez; Peter H Custis; Vaishali Patel; Joanna H Campbell Journal: Retina Date: 2018-09 Impact factor: 4.256